KR20180014009A - 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합 - Google Patents

암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합 Download PDF

Info

Publication number
KR20180014009A
KR20180014009A KR1020177037185A KR20177037185A KR20180014009A KR 20180014009 A KR20180014009 A KR 20180014009A KR 1020177037185 A KR1020177037185 A KR 1020177037185A KR 20177037185 A KR20177037185 A KR 20177037185A KR 20180014009 A KR20180014009 A KR 20180014009A
Authority
KR
South Korea
Prior art keywords
ser
leu
seq
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177037185A
Other languages
English (en)
Korean (ko)
Inventor
잉 유
앤드류 에반 덴커
스베틀라나 사데코바
우옌 쯔엉 판
로버트 에이. 카스텔라인
데이비드 로스 카우프만
로버트 엘. 코프먼
크리스티아나 귀두치
로버트 에스. 얀센
Original Assignee
머크 샤프 앤드 돔 코포레이션
다이나박스 테크놀로지 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션, 다이나박스 테크놀로지 코퍼레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20180014009A publication Critical patent/KR20180014009A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020177037185A 2015-05-29 2016-05-26 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합 Withdrawn KR20180014009A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US62/168,449 2015-05-29
US201562169309P 2015-06-01 2015-06-01
US62/169,309 2015-06-01
PCT/US2016/034275 WO2016196173A1 (en) 2015-05-29 2016-05-26 Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer

Publications (1)

Publication Number Publication Date
KR20180014009A true KR20180014009A (ko) 2018-02-07

Family

ID=57441888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177037185A Withdrawn KR20180014009A (ko) 2015-05-29 2016-05-26 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합

Country Status (13)

Country Link
US (2) US10751412B2 (https=)
EP (2) EP3302501B1 (https=)
JP (2) JP6893608B2 (https=)
KR (1) KR20180014009A (https=)
CN (1) CN108025018B (https=)
AU (1) AU2016271018A1 (https=)
BR (1) BR112017025562A2 (https=)
CA (1) CA2986126A1 (https=)
ES (1) ES2985394T3 (https=)
MA (1) MA44699A (https=)
MX (1) MX2017015308A (https=)
RU (1) RU2017145558A (https=)
WO (1) WO2016196173A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN105209881B (zh) 2013-03-13 2021-01-22 迈阿密大学 从细胞培养上清液和生物流体分离并纯化微泡的方法
JP6991857B2 (ja) * 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
DK3240801T3 (da) * 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
US12310999B2 (en) 2017-04-28 2025-05-27 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
EA202090565A1 (ru) 2017-10-13 2020-10-13 Мерк Шарп энд Доум Корп. Композиции и способы лечения диффузной в-крупноклеточной лимфомы
CA3075294A1 (en) 2017-10-27 2019-05-02 Merck Sharp & Dohme Corp. Compositions and methods for treating liver cancer
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
KR102890791B1 (ko) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
WO2019200238A1 (en) * 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) * 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
EP3896085A4 (en) * 2018-12-12 2022-11-30 Shanghai Pharmaexplorer Co., Ltd. MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN 5 (IL-5) AND ITS USE
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
TWI833056B (zh) * 2019-12-31 2024-02-21 財團法人工業技術研究院 核酸藥物複合體以及其用途
IL294621A (en) * 2020-01-10 2022-09-01 Sbi Biotech Co Ltd Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof
CN116724118A (zh) * 2020-07-24 2023-09-08 利兰斯坦福初级大学董事会 Covid-19的三组分疫苗
DE112021004970T5 (de) * 2020-09-22 2023-07-06 Trisalus Life Sciences, Inc. Krebstherapie unter verwendung von toll-like-rezeptor-agonisten
CN116685330A (zh) * 2020-09-22 2023-09-01 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法
KR20230121995A (ko) * 2020-09-22 2023-08-22 트라이살루스 라이프 사이언시즈, 인크. 톨-유사 수용체 작용제를 사용한 암 요법
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用
CN117561066A (zh) * 2021-04-01 2024-02-13 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法
JP2024512765A (ja) * 2021-04-01 2024-03-19 トリサルース・ライフ・サイエンシズ・インコーポレイテッド トール様受容体アゴニストを使用したがん治療
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023081486A1 (en) 2021-11-08 2023-05-11 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
WO2025233224A1 (en) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
EP0879284B1 (en) 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DK1009413T3 (da) 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
JP4188687B2 (ja) 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション 免疫変調ポリヌクレオチド及びその使用法
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PT1992635E (pt) * 2002-12-23 2012-03-20 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
PE20050925A1 (es) * 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP3912643B8 (en) * 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
ES2676205T3 (es) * 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2981821B2 (en) * 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
CA2917858A1 (en) * 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
MX2016004570A (es) 2013-10-11 2016-09-08 Genentech Inc Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
WO2015167616A1 (en) 2014-05-02 2015-11-05 Nitor Therapeutics Guanosine as an immunepotentiator mediated through toll receptors
JP6991857B2 (ja) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
DK3240801T3 (da) * 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
JP2018516252A (ja) 2015-05-29 2018-06-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のための抗ＩＬ−１０抗体とＣｐＧ−Ｃ型オリゴヌクレオチドの併用
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

Also Published As

Publication number Publication date
MX2017015308A (es) 2018-07-06
JP7236483B2 (ja) 2023-03-09
CA2986126A1 (en) 2016-12-08
ES2985394T3 (es) 2024-11-05
CN108025018B (zh) 2021-08-17
EP3302501A1 (en) 2018-04-11
US11918648B2 (en) 2024-03-05
JP6893608B2 (ja) 2021-06-23
US20180169229A1 (en) 2018-06-21
EP3892284A1 (en) 2021-10-13
JP2021102627A (ja) 2021-07-15
RU2017145558A (ru) 2019-07-01
WO2016196173A1 (en) 2016-12-08
MA44699A (fr) 2021-05-05
EP3302501B1 (en) 2021-09-22
AU2016271018A1 (en) 2017-11-30
EP3892284B1 (en) 2024-05-22
US20210196819A1 (en) 2021-07-01
BR112017025562A2 (pt) 2018-08-07
HK1252652A1 (zh) 2019-05-31
JP2018516911A (ja) 2018-06-28
US10751412B2 (en) 2020-08-25
EP3302501A4 (en) 2019-02-27
CN108025018A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
US11918648B2 (en) Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer
TWI663983B (zh) 用於治療癌症之ｐｄ－１拮抗劑及ｖｅｇｆｒ抑制劑之組合
EP3283527B1 (en) Combination therapy for cancer
US20180161427A1 (en) Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
KR20170004006A (ko) 암을 치료하기 위한 항-ｃｃｒ4 항체 및 4-1ｂｂ 효능제의 조합
CN110753756A (zh) 免疫调节性多核苷酸及其应用
US11542335B2 (en) Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R)
US20210403557A1 (en) Dosing regimen of anti-tigit antibody for treatment of cancer
CN115996950A (zh) 抗tnfr2抗体和其用途
CN117980336A (zh) 抗tnfr2抗体及其用途
HK40060963A (en) Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
HK40060963B (en) Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
KR20220151161A (ko) Igsf8의 표적화에 의해 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
HK1252652B (en) Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
HK40008965A (en) Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20210226

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid